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Abstract
AIM: To assess the distribution of human leukocyte 
antigen (HLA)-DQ2 and -DQ8 in Iranian celiac disease 
(CD) patients and compare them to healthy Iranian 
controls. 
METHODS: To predict the HLA-DQA1 and -DQB1 
genes, we used six previously reported HLA-tagging 
single nucleotide polymorphism to determine HLA 
genotypes in 59 Iranian patients with ‘biopsy-confirmed’ 
CD and in 151 healthy Iranian individuals. To test the 
transferability of the method, 50 cases and controls 
were also typed using a commercial kit that identifies 
individual carriers of DQ2, DQ7 and DQ8 alleles.
RESULTS: In this pilot study 97% of CD cases (n  = 
57) and 58% of controls (n  = 87) were carriers of HLA-
DQ2 and/or HLA-DQ8 heterodimers, either in the ho-
mozygous or heterozygous state. The HLA-DQ pattern 
of these 57 CD patients: heterozygous DQ2.2 (n  = 14) 
and homozygous DQ2.2 (n  = 1), heterozygous DQ2.5 (n  
= 33) and homozygous DQ2.5 (n  = 8), heterozygous 
DQ8 (n  = 13) and homozygous DQ8 (n  = 2). Two CD 
patients were negative for both DQ2 and DQ8 (3%). 
CONCLUSION: The prevalence of DQ8 in our CD pop-
ulation was higher than that reported in other popula-
tions (25.4%). As reported in other populations, our 
results underline the primary importance of HLA-DQ 
alleles in the Iranian population’s susceptibility to CD.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Human leukocyte antigen typing; Valida-
tion; Susceptibility; Celiac disease; Iran
Core tip: We describe, for the first time, the distribution 
of human leukocyte antigen (HLA)-DQ2/DQ8 alleles in 
Iranian celiac disease patients compared to healthy Ira-
nian controls. To assess this distribution we applied a 
single nucleotide polymorphism-based approach, which 
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was developed in European (Caucasian) study samples. 
We also demonstrate the transferability of such an ap-
proach to the Iranian population. Our results underline 
the primary importance of HLA-DQ alleles in the Iranian 
population’s susceptibility to celiac disease.
Rostami-Nejad M, Romanos J, Rostami K, Ganji A, Ehsani-
Ardakani MJ, Bakhshipour AR, Zojaji H, Mohebbi SR, Zali 
MR, Wijmenga C. Allele and haplotype frequencies for HLA-
DQ in Iranian celiac disease patients. World J Gastroenterol 




Celiac disease (CD) is characterized by malabsorption of  
nutrients in the small intestine after ingestion of  wheat 
gluten or related proteins from rye and barley. The dis-
ease is characterized by villous atrophy of  the small intes-
tinal mucosa. With adherence to a strict gluten-free diet, 
most CD patients show prompt clinical and histological 
improvement, with relapse of  the symptoms if  gluten is 
re-introduced[1-3]. Similar to Western studies, a high preva-
lence of  CD has been reported in Iranian general popula-
tion (about 1%)[3].
Many studies reflect the importance of  genetic factors 
in the pathogenesis of  CD[3]. A recent study by Anderson 
et al[4] suggested that a combination of  human leukocyte 
antigen (HLA) typing and confirmatory serology could 
decrease the number of  unnecessary endoscopies.
The HLA-DQ2 heterodimer, which is coded by al-
leles DQA1*05 and DQB1*02, is present in the vast 
majority of  CD patients including approximately 95% of  
CD patients of  Northern-European descent[4]. The most 
important risk factor for CD is the DQ2.5 haplotype[4]. 
Alpha and beta chains of  this heterodimer are encoded 
together in cis (DQA1*05 and DQB1*02) on a DRB1*03 
haplotype. Other DQ heterodimers that are encoded in 
trans on DR7 haplotypes are related to the DQ2.2 hap-
lotype (DQA1*0201/DQB1*02)[5-13]. Those CD patients 
who do not carry the DQ2 heterodimer, and are encoded 
by the DR4 haplotype, carry HLA-DQ8 (a1*0301, 
β1*0302)[4]. HLA-DQ2 is common in Europeans and is 
expressed in 25%-30% of  the healthy European popula-
tion. Most of  the CD patients who do not carry either 
DQ2.5 or DQ8, carry half  of  the DQ2.5 or DQ2.2 mol-
ecule (that is either HLA-DQA1*05 or HLA-DQB1*02), 
suggesting that carrying even some of  the risk molecules 
still has functional implications for the risk of  CD[13]. The 
majority of  studies of  HLA in CD are focused on Cau-
casian populations and detailed information on patient 
cohorts from diverse ethnic groups is lacking.
There are a number of  ethnic groups in Iran, in-
cluding Persians (Fars), Kurds, Lours, Arabs, Turkmen, 
Balochs, and Turks. Most Iranians are Muslims but Zoro-
astrians, Jews, Armenians, and Nestorians also live in this 
large country. Based on previous studies in Iran, the most 
common HLA haplotype in the different ethnic groups 
is DQ2 and DQ7, with reported prevalences of  22.1% 
and 25%, respectively[14-17] (Figure 1). These studies were 
performed in healthy populations in different parts of  
the country and found considerable similarities in the 
distribution of  HLA class Ⅱ haplotypes with European 
countries. However, Iranian CD patients have never been 
studied for HLA.
Recently, Monsuur et al[13] described an HLA-tagging 
single nucleotide polymorphism (SNP) method for de-
tecting the HLA risk alleles for CD. Using six SNPs, 
HLA genotyping for specific CD genotypes could be per-
formed in a high-throughput mode. The results of  Mon-
suur et al[13] and Koskinen et al[12] showed that the sensi-
tivity and specificity of  this test in recognizing DQ2.2, 
DQ2.5, DQ7, and DQ8 haplotypes was > 99% in the 
Dutch population, and > 98% in the United Kingdom, 
Spanish, Finnish, Hungarian, and Italian populations. 
The main aim of  this study was to provide new infor-
mation on HLA-DQ associations with CD in the Iranian 
patients, which has never been investigated before, by us-
ing the tagging SNP method.
MATERIALS AND METHODS
Patients 
A total of  59 CD patients (21 males and 38 females, me-
dian age 30.5 years, range 7-67 years) were included: 12 
patients from East Iran (Zahedan Province, Baloch eth-
nicity), 13 from North Iran (Mashhad Province, Fars), 10 
from West Iran (Lorestan and Kurdistan Provinces, Lour 
and Kurd ethnic groups), and 24 patients from Tehran, in 
the center of  Iran (Fars). All patients had positive tTGA 
and/or EMA antibodies and histology according to the 
Rostami-Marsh classification (Marsh Ⅰ-Ⅲc)[18].
Controls
A total of  151 healthy controls (78 females and 73 males, 
median age 32.7 years, range 5-83 years) were selected 
from those who were negative for CD serological screen-
ing in the study areas (25 from Zahedan Province, 30 
from Mashhad, 26 from Lorestan and Kurdistan prov-
inces, and 70 from Tehran) and matched by age and sex. 
None of  them had a personal or family history of  cancer 
or autoimmune diseases. The study was approved by the 
ethical committees of  the Gastroenterology and Liver 
Diseases Research Centers, Shahid Beheshti University 
of  Medical Sciences, Tehran, and all the participants (or 
their parents/guardians) were informed about the study 
according to the study protocol and gave their written 
informed consent.
HLA typing
DNA was extracted using the phenol chloroform meth-
od[19]. The six HLA-tagging SNPs reported by Monsuur 
et al[13] were genotyped using 5 ng of  DNA from the Ira-
nian participants, and using TaqMan chemistry and cus-
tom assays from Applied Biosystems (ABI, Foster City, 
Rostami-Nejad M et al . HLA typing in Iranian celiac disease patients
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CA, United States, www.appliedbiosystems.com), includ-
ing DQ2.2 (rs2395182 and rs7775228 SNPs for DQ2.2, 
and rs4713586 SNP to exclude DQ4 from the DQ2.2 
group), and SNPs rs2187668 (DQ2.5), rs4639334 (DQ7), 
and rs7454108 (DQ8). DNA was genotyped using a 
standard protocol provided by Applied Biosystems. The 
PCR assays and allelic discrimination were run using an 
ABI PRISM 7900HT Sequence Detection System (SDS) 
machine. All individuals were run on the same 384-well 
plate to avoid biased results due to technical issues. The 
data was analyzed using SDS program 2.3 (Applied Bio-
systems). 
Validation
The HLA alleles for 20 CD cases and 30 controls were 
also typed using a commercial kit (BAG, Germany) which 
is commonly used in general diagnostic laboratories. The 
BAG kit makes it possible to identify individuals who 
are carriers of  the DQB1*02, DQB1*0301, DQA1*05 
or DQA1*0201 alleles for HLA-DQ2; DQB1*0302 or 
DQA1*03 for HLA-DQ8; and DQB1*0301 for HLA-
DQ7. We could thus distinguish DQ2.5-positive indi-
viduals from those who have DQ2.2.
Analysis 
For the prediction of  HLA alleles, we inferred the DQ 
types from the tag SNPs according to the method de-
scribed by Monsuur et al[13]. Only individuals with com-
plete histology and serology data were included in this 
study (59 cases). The statistical analysis was performed 
using the F-test. The correlation between HLA risk al-
leles and Marsh classification was also investigated. A 
P-value less than 0.05 was considered statistically sig-
nificant. Power calculations were performed using the 
Quanto program (http://hydra.usc.edu/gxe/) assuming 
allele frequencies of  0.15-0.30 and an odds ratio of  6.
RESULTS
Testing the tag SNPs 
We first evaluated the 59 CD patients and 151 controls 
for prediction of  related HLA genotypes by TaqMan 








Studied population City Prevalence Ethnicity HLA typing
HLA typing in this study
Tehran 38.6% Fars HLADQ2/7/8
Mashhad 22.8% Fars HLADQ2/7/8
Lorestan   8.8% Lur HLADQ2/7/8
Kurdistan   8.8% Kurd HLADQ2/7/8
Sistan Baluchestan    21% Baloch HLADQ2/7/8
HLA typing from 
previous studies
Fars    25% Fars HLA DQ7
Kurdistan 17.5% Kurd HLA DQ7
East Azarbaijan, West Azarbaijan and Ardebil    11% Azari HLA DQ7
Sistan Baluchestan 22.1% Baloch HLA DQ2
Kerman and Yazd 20.8% Zoroastrian HLA DQ2
Figure 1  Human Leukocyte antigenhaplotype frequencies in the different ethnicities of Iran[14-17]. HLA: Human leukocyte antigen. 
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between the two tests. Eight CD samples, which the tag 
SNP approach classified as non-DQ2/DQ8, were typed 
as DQ8 with the BAG kit. The results of  the validation 
showed that the sensitivity to detect DQ2 and DQ7 was 
100% and 84.6% for DQ8, while the specificity was 97% 
for DQ2 and DQ7, and 86.4% for DQ8 (Table 2). These 
results suggest that DQ2 and DQ7 can be inferred using 
the tag-SNP method, but that the detection of  DQ8 is 
less sensitive and less specific. Heterozygosity and homo-
zygosity of  the haplotypes could not be determined by 
the BAG kit for all samples, especially when the parallel 
haplotypes are unknown (DQX). 
Risk groups
Based on the outcome of  the HLA-DQ2/DQ8 predic-
tion using tagging SNPs, we divided the Iranian popula-
tion into three risk groups: low risk, which were DQ2/
DQ8-negative (3.4% of  cases, 43.7% of  controls); inter-
mediate risk, which were homozygous for DQ2.2 and 
DQ8, or heterozygous for DQ8, DQ2.5 or DQ2.2 (71.2% 
of  cases, 52.3% of  controls); and high risk, which were 
homozygous DQ2.5 or DQ2.5/DQ2.2) (25.4% of  cases, 
4% of  controls) (Figure 2). The differences were statisti-
cally significant for all the risk groups when comparing 
cases to controls (P < 0.05). We also confirmed that CD 
patients carry more HLA risk alleles than healthy con-
trols and this difference was statistically significant for the 
DQ2.5 haplotype distribution between cases and controls 
(P = 0.0001).
Ethnic heterogeneity 
We included individuals from four areas with different 
ethnicities in Iran but did not find any statistical differ-
ence in the distribution of  HLA-DQ2 and HLA-DQ7 
genotypes in either the case or control groups (P > 0.05) 
(data not shown).
Marsh classification
Fourteen patients with Marsh Ⅰ histology and 12 with 
Marsh Ⅱ were compared to 33 patients with Marsh Ⅲ 
(including 14 Marsh Ⅲa, 7 Marsh Ⅲb and 13 Marsh Ⅲc) 
in relation to their HLA-DQ haplotypes. Table 3 shows 
the distribution of  HLA haplotypes according to the 
Rostami-Marsh classification[18]. Of  the 25 patients dem-
onstrating only minor small bowel mucosal changes (i.e., 
SNPs. We observed that 83.03% of  cases and 35.09% 
of  controls were carriers of  an HLA-DQ2 heterodimer, 
either in homozygous or heterozygous state. The pat-
terns of  the specific HLA-DQ haplotypes in the CD 
patients were as follows: 25.4% of  CD patients were het-
erozygous DQ2.2 including DQ2.2/DQ2.5 compound 
heterozygosity, 1.7% of  CD patients were homozygous 
DQ2.2/DQ2.2, 56% of  CD patients were heterozygous 
DQ2.5 including DQ2.5/DQ8 compound heterozygos-
ity, and 13.5% of  CD patients were homozygous DQ2.5/
DQ2.5. DQ8 heterozygosity was predicted in 15 patients, 
of  which seven were DQ8/DQ2.5 carriers and two were 
homozygous DQ8/DQ8. The HLA-DQ pattern in the 
controls was as follows: heterozygous DQ2.2 in 28.5%, 
non-homozygous DQ2.2/DQ2.2, and heterozygous 
DQ2.5 in 16.5%, and homozygous DQ2.5/DQ2.5 in 
one. DQ8 was positive in the heterozygous state in 30 
(19.9%) controls and in the homozygous state in four 
controls. 
Table 1 shows the frequency of  HLA-related CD 
genotypes in the healthy controls and the prevalence of  
the different HLA-related CD genotypes in our Iranian 
CD patients. DQ2.2 and DQ7 can only confer risk of  
CD when both are present together or with DQ2.5[13]. 
In our cohort, DQ2.2 and DQ7 haplotypes were present 
together or with DQ2.5 in 23.7% of  CD patients and 
11.9% of  controls. A DQ2-DQ8-negative genotype was 
seen in 66 controls and two CD cases. 
DQ2.5/DQ2.2, DQ2.5/DQ2.5, DQ2.5/DQ8 and 
DQ2.5/DQX were detected as significant in the CD 
cases (P < 0.05) and DQ7/DQ7 and DQ7/DQX were 
detected as significant in the controls (P < 0.05). Accord-
ingly, we can conclude that CD patients carry more HLA 
risk alleles than controls (Table 1). 
Validation of the tag SNPs
We typed 20 random CD cases and 30 controls using 
both the BAG kit and the tag SNPs to test the valid-
ity of  the tag SNP approach in the Iranian population. 
Nine cases and three controls showed discordant results 
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Table 1  Frequency of human leukocyte antigenhaplotypes in 
Iranian cases and controls  n  (%)
Genotypes Cases Controls P -value 
DQ2.2/DQ2.2   1 (1.7) 0 (0)  0.28
DQ2.2/DQ7   4 (6.8)   8 (5.3)  0.76
DQ2.2/DQX     3 (5.08)   22 (14.5)  0.06
DQ2.5/DQ2.2     7 (11.9)   5 (3.3)  0.04
DQ2.5/DQ2.5     8 (13.6)   1 (0.6) < 0.001
DQ2.5/DQ7     3 (5.08)   5 (3.3)  0.69
DQ2.5/DQ8     7 (11.9)   5 (3.3)  0.04
DQ2.5/DQX   16 (27.1) 10 (6.6) < 0.001
DQ7/DQ7 0 (0)   17 (11.2)    0.004
DQ7/DQX 0 (0)   17 (11.2)    0.004
DQ8/DQ2.2 0 (0)   8 (5.3)  0.11
DQ8/DQ7   1 (1.7) 9 (6)  0.29
DQ8/DQ8   2 (3.3)   4 (2.6)  0.67
DQ8/DQX   5 (8.5)   8 (5.3)  0.54
DQX/DQX   2 (3.3)   32 (21.2)    0.001
Total 59 (100) 151 (100)
Table 2  Validation results in the Iranian population using the 




Number of patients   59 151
DQ 2.2 Sensitivity 100% 100%
Specificity 100% 100%
DQ 2.5 Sensitivity 100% 100%
Specificity 97.8% 96.7%
DQ 8 Sensitivity 86.4% 100%
Specificity 86.4% 97.1%
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Marsh Ⅰ and Ⅱ histology), two (3.4%) were negative for 
DQ2 and DQ8. Our result thus confirmed that patients 
with Marsh Ⅰ or Ⅱ histology carry low HLA risk alleles, 
such as HLA-DQ8. No statistically significant correla-
tions were detected between the corresponded haplo-
types and the different Marsh classifications.
DISCUSSION
Several epidemiological studies indicated that CD is a 
common disorder in the Iranian population with a preva-
lence of  1%[20-22], but there are no data on the frequency 
of  HLA-related CD-predisposing alleles. We examined 
the frequency of  the HLA-DQA1 and HLA-DQB1 hap-
lotypes in Iranian CD patients and compared them to a 
matched, healthy control group.
A simple PCR-based SNP approach has been de-
veloped for large-scale population screening[13] and this 
method can be applied to different Caucasian popula-
tions[12]. A major advantage of  this PCR-based SNP 
method is its ability to distinguish HLA-DQ2 and HLA-
DQ8 homozygotes and heterozygotes which, in turn, 
translates into differences in the risk carried for CD. We 
tested the transferability of  this method to the Iranian 
population and found that the sensitivity and specific-
ity to detect the CD risk alleles was 100% and 97% for 
HLA-DQ2 and HLA-DQ7, respectively, but slightly 
lower for HLA-DQ8 (86.4%). 
The lower sensitivity and specificity for HLA-DQ8 
in the Iranian population might be attributable to differ-
ences in the patterns of  linkage disequilibrium blocks in 
Iranians and Europeans. The frequency of  the HLA hap-
lotypes in Iran is not necessarily different from Europe-
ans, but the tagging SNP method might not be the ideal 
test to establish the frequency of  CD-associated HLA-
DQ8 haplotypes in this population.
The false positives or false negatives observed with 
the tagging SNP method may be due to the presences of  
rare alleles (DQX) either in heterozygous or homozygous 
state that cannot be detected by the BAG kit.
As reported for other populations[23-25], the most fre-
quent haplotype in Iranian CD patients was HLA-DQ2.5 
(69.5%) and its frequency is very similar to that seen in 
European CD populations. 
Surprisingly, in contrast to the low prevalence of  
HLA-DQ8 in CD population reported in the literature 
(0.6% in Cameroon, 2% in Italy, 2.3% in Hungary, 4.2% 
in United States, 6.4% in Finland and 7.6% in Japan)[12,26], 
we found a higher prevalence (25.4%) of  this genotype in 
the Iranian CD population. Our result is comparable with 
those presented by Catassi et al[27] in 2009 for Turks (22%), 
North American Indians (25.3%), Mexicans (28.3%) and 
Bushmen (ethnic groups in Southern Africa) (30%). 
Karell et al[28] and Polvi et al[29] suggested that only a 
small number of  CD patients (6%) carry neither DQ2 nor 
DQ8. Our study supports these figures, as we only found 
two CD patients (3.4%) who were DQ2-DQ8-negative. 
Several studies have shown that individuals homo-
zygous for HLA-DQ2.5 or heterozygous for HLA-
DQ2.5/DQ2.2 genotypes have an increased risk for 
CD compared to those homozygous for HLA-DQ2.2 
or heterozygous for HLA-DQ2.5 or HLA-DQ2.2[30-32]. 
Similarly, our results show that 25.4% of  cases lie in the 
high risk group for CD compared to 3.4% in the low risk 
group. The frequencies of  intermediate risk and high risk 
groups were, as expected, higher in cases than controls 
(Figure 2). 
The frequency of  DQ8/DQ2.2 in the cases was zero 
but this number may be less reliable. This may be due 
to differences in the patterns of  linkage disequilibrium 
blocks in Iranians or may result from low concentrations 
of  DNA samples (the concentration of  the samples was 
reduced when they were sent to the UMCG for genetic 
analysis). We concluded that DQ2 worked well, but DQ8 
needs to be interpreted more carefully when identified 
using tagging SNPs.
In conclusion, this pilot study has provided informa-
tion on the genetic background of  CD in Iranians. This 
should prove useful to other researchers and to future 
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Table 3  Distribution of human leukocyte antigen haplotypes 
according to the degrees of mucosal changes
Haplotype Rostami-Marsh classification Total P -value
Marsh Ⅰ Marsh Ⅱ Marsh Ⅲ
HLA- DQ2.2/DQ2.2   0   0   1   1   0.73
 DQ2.2/DQ7   0   2   2   4   0.46
 DQ2.2/DQX   1   0   2   3 0.2
 DQ2.5/DQ2.2   1   3   3   7   0.06
 DQ2.5/DQ2.5   1   2   5   8   0.46
 DQ2.5/DQ7   2   0   1   3 0.2
 DQ2.5/DQ8   1   1    5   7   0.78
 DQ2.5/DQX   5   2   9 16   0.96
 DQ8/DQ7   0   1   0   1   0.04
 DQ8/DQ8   0   0   2   2   0.53
 DQ8/DQX   0   2   3   5   0.13
 DQX/DQX   1   0   1   2   0.64





















Figure 2  Distribution of the human leukocyte antigen risk groups in cases 
and controls according to tag-single nucleotide polymorphism prediction. 
Low risk for those negative for DQ2/DQ8; intermediate risk for those homo-
zygous for HLA-DQ2.2 or DQ8, heterozygous for DQ2.5 or DQ2.2; high risk 
for those homozygous for DQ2.5 and DQ2.5/DQ2.2. HLA: Human leukocyte 
antigen. 
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work on this disease. Despite our small cohort, the data 
we present offer a first step towards defining the genetic 
structure of  HLA in the Iranian population with CD and 
provide information that can be used in family screening. 
In addition, our data suggest that the Iranian population, 
as a non-European Caucasian population, does share 
certain HLA class Ⅱ genetic components with the CD 
populations of  European ancestry. We found that Ira-
nians are most similar to non-European Caucasian CD 
patients, given their increased frequency of  HLA-DQ8 
carriers. Further works, with larger sample sizes, on HLA 
polymorphisms among people living in different parts 
of  Iran will provide more detailed information about the 
genetic background of  the Iranian population and its re-
lationship to other ethnic populations in the world.
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Celiac disease (CD) is caused by an immune response to gluten in genetically 
predisposed individuals. This disease is strongly associated with human leu-
kocyte antigen (HLA)-DQ2 or DQ8 genotypes. HLA molecules are postulated 
to present gluten antigens to T-cells, which in turn induce tissue damage. Ap-
proximately 95% of patients with CD have the HLA-DQ2 heterodimer encoded 
by the DQA1*05 and DQB1*02 alleles, while close to 5% have the HLA-DQ8 
heterodimer encoded by the DQA1*03 and DQB1*0302 alleles. The HLA-DQ 
alleles are also found in 48%-65% of first-degree relatives of patients with CD 
and the general population. 
Research frontiers
HLA-DQ2 and -DQ8 determination is useful in the exclusion, probably lifelong, 
of celiac disease in individuals with an equivocal small bowel histological find-
ing.
Innovations and breakthroughs
This describe, for the first time, the distribution of HLA-DQ2/DQ8 alleles in 
Iranian celiac disease patients compared to healthy Iranian controls. To as-
sess this distribution their authorized a novel SNP method to assess HLA 
distribution. They also demonstrate the transferability of such an approach to 
the Iranian population. The results underline the primary importance of HLA-
DQ alleles in the Iranian population’s susceptibility to celiac disease. This show 
that the frequency of HLA-DQ2 is higher in Iranian celiac disease patients than 
in controls and that the prevalence of HLA-DQ8 is higher than that reported in 
other international populations. The data presented in this study offer the first 
step towards defining the genetic structure of HLA in the Iranian population with 
celiac disease and provide information that can be used in family screening. In 
addition, the data suggest that the Iranian population, as a non-European Cau-
casian population, does share certain HLA class Ⅱ genetic components with 
the populations of European countries. They therefore suggest that performing 
readily available serological tests in combination with HLA typing will signifi-
cantly reduce the burden of celiac disease in the at-risk population by providing 
more accurate diagnoses and enabling timely treatment with a gluten-free diet.
Applications
The main importance of HLA mapping is to combine the less-invasive methods 
into a diagnostic algorithm that can be a substitute for the gold standard of 
biopsy sampling. Carrying HLA risk alleles can be a predictor of susceptibility to 
celiac disease.
Terminology
HLA: the loci of genes that encode for major histocompatibility complex in hu-
mans; tissue transglutaminase IgA and/or IgG test: autoantibodies against the 
transglutaminase protein used as part of an evaluation for certain autoimmune 
conditions, most notably celiac disease.
Peer review
The authors have aimed to identify the prevalence of HLA-DQ2 and -DQ8 al-
leles in celiac patients and a healthy population in Iran and have compared 
the results with those determined by previously described tagging single 
nucleotide polymorphism (SNP) methods and commercial kits. The reviewed 
article describes a nice study. Indeed, there were no data available on the HLA 
distribution in celiac patients in Iran. Furthermore, the approach based on HLA-
tagging SNPs that was adopted in this study is the best described method for 
determining HLA alleles. The article is well written, and the tables and figures 
are of outstanding quality. It is thus a great summary of a pilot study conducted 
in Iranian celiac patients.
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